|
Volumn 126, Issue 6, 2015, Pages 739-745
|
Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results
a b c d e f g h a i j k l m n o p q a r more.. |
Author keywords
[No Author keywords available]
|
Indexed keywords
IBRUTINIB;
AGAMMAGLOBULINAEMIA TYROSINE KINASE;
ANTINEOPLASTIC AGENT;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
ABDOMINAL PAIN;
ACUTE KIDNEY FAILURE;
ADULT;
AGED;
ANEMIA;
ARTHRALGIA;
ARTICLE;
ATRIAL FIBRILLATION;
BACKACHE;
BLEEDING;
BONE MARROW BIOPSY;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CELLULITIS;
COMPUTER ASSISTED TOMOGRAPHY;
CONSTIPATION;
CONTUSION;
DIARRHEA;
DRUG EFFICACY;
DRUG SAFETY;
DYSPNEA;
FATIGUE;
FEBRILE NEUTROPENIA;
FEVER;
FOLLOW UP;
HEMATURIA;
HUMAN;
HYPERURICEMIA;
MAJOR CLINICAL STUDY;
MANTLE CELL LYMPHOMA;
MULTICENTER STUDY;
MYALGIA;
NAUSEA;
NEUTROPENIA;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PERIPHERAL EDEMA;
PHASE 2 CLINICAL TRIAL;
PNEUMONIA;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RASH;
RISK ASSESSMENT;
SINUSITIS;
SUBDURAL HEMATOMA;
THROMBOCYTOPENIA;
TREATMENT DURATION;
TREATMENT RESPONSE;
UPPER RESPIRATORY TRACT INFECTION;
URINARY TRACT INFECTION;
VOMITING;
CHEMICALLY INDUCED;
CLINICAL TRIAL;
DRUG ADMINISTRATION;
FEMALE;
LYMPHOMA, MANTLE-CELL;
MALE;
MIDDLE AGED;
MORTALITY;
ORAL DRUG ADMINISTRATION;
PATHOLOGY;
PATHOPHYSIOLOGY;
RECURRENT DISEASE;
SURVIVAL;
TREATMENT OUTCOME;
VERY ELDERLY;
ADMINISTRATION, ORAL;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC AGENTS;
DIARRHEA;
DRUG ADMINISTRATION SCHEDULE;
DYSPNEA;
FATIGUE;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
LYMPHOMA, MANTLE-CELL;
MALE;
MIDDLE AGED;
NAUSEA;
NEUTROPENIA;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
RECURRENCE;
SURVIVAL ANALYSIS;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
|
EID: 84938752545
PISSN: 00064971
EISSN: 15280020
Source Type: Journal
DOI: 10.1182/blood-2015-03-635326 Document Type: Article |
Times cited : (354)
|
References (14)
|